If Novo Nordisk A/S’s wildly popular weight-loss drug succeeds in a highly anticipated trial for Alzheimer’s disease, Biogen Inc.’s Chief Executive Officer Chris Viehbacher doesn’t see it as a ...

A new study connects PFA or forever chemical exposure to incident type 2 diabetes risk. Experts explain the findings and how ...